Clinical Trial Update: Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia. [Phase 3]

View source ↗

Summary

An open-label Phase 3 study evaluated flexible-dose paliperidone extended-release for treating adolescent schizophrenia; results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Paliperidone ER (paliperidone)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Schizophrenia, Schizophrenic Disorders | Phase 3 | Status: COMPLETED | Results posted: 2014-01-06